Comparative Pharmacology
Head-to-head clinical analysis: LANSOPRAZOLE AMOXICILLIN AND CLARITHROMYCIN COPACKAGED versus PRILOSEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LANSOPRAZOLE AMOXICILLIN AND CLARITHROMYCIN COPACKAGED versus PRILOSEC.
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED) vs PRILOSEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lansoprazole is a proton pump inhibitor that irreversibly inhibits the H+/K+ ATPase enzyme system (proton pump) at the secretory surface of gastric parietal cells, suppressing basal and stimulated gastric acid secretion. Amoxicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis. Clarithromycin is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis.
Omeprazole is a proton pump inhibitor that irreversibly inhibits the H+/K+-ATPase enzyme system at the secretory surface of gastric parietal cells, thereby blocking the final step of gastric acid secretion.
Each dose: Lansoprazole 30 mg, Amoxicillin 1000 mg, Clarithromycin 500 mg administered orally twice daily for 10-14 days.
20 mg orally once daily before a meal for 4-8 weeks for GERD; for duodenal ulcer, 20 mg once daily for 4 weeks; for Zollinger-Ellison syndrome, initial dose 60 mg orally once daily, titrate up to 120 mg three times daily as needed.
None Documented
None Documented
Lansoprazole: ~1.5 h (prolonged in hepatic impairment); Amoxicillin: ~1-1.5 h (prolonged in renal impairment); Clarithromycin: ~3-4 h (6-9 h for 14-hydroxy metabolite).
Terminal elimination half-life: 0.5–1 hour in healthy subjects (elimination phase); clinical context: acid suppression persists >24 hours due to irreversible binding to parietal cell H+/K+-ATPase.
Lansoprazole: primarily hepatic metabolism, ~33% renal (metabolites), ~67% fecal; Amoxicillin: ~60-80% renal unchanged; Clarithromycin: ~20-30% renal unchanged, ~50% hepatic metabolism, ~30% fecal.
Renal: ~77% as metabolites; fecal: ~20% as metabolites (biliary/fecal). Unchanged drug negligible.
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor